11/16
08:59 am
dnli
Denali Has A Neurodegenerative Edge Despite Market Skepticism [Seeking Alpha]
Medium
Report
Denali Has A Neurodegenerative Edge Despite Market Skepticism [Seeking Alpha]
11/15
08:48 am
dnli
We're Hopeful That Denali Therapeutics (NASDAQ:DNLI) Will Use Its Cash Wisely [Yahoo! Finance]
High
Report
We're Hopeful That Denali Therapeutics (NASDAQ:DNLI) Will Use Its Cash Wisely [Yahoo! Finance]
11/8
11:57 am
dnli
Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging [Yahoo! Finance]
Medium
Report
Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging [Yahoo! Finance]
11/7
08:36 am
dnli
Denali Therapeutics Inc. (NASDAQ: DNLI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Low
Report
Denali Therapeutics Inc. (NASDAQ: DNLI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
11/7
02:45 am
dnli
Denali Therapeutics GAAP EPS of -$0.63 [Seeking Alpha]
Low
Report
Denali Therapeutics GAAP EPS of -$0.63 [Seeking Alpha]
11/6
04:01 pm
dnli
Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
Low
Report
Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
11/1
01:38 pm
dnli
Denali Therapeutics Inc. (NASDAQ: DNLI) had its price target raised by analysts at Jefferies Financial Group Inc. from $40.00 to $45.00. They now have a "buy" rating on the stock.
Low
Report
Denali Therapeutics Inc. (NASDAQ: DNLI) had its price target raised by analysts at Jefferies Financial Group Inc. from $40.00 to $45.00. They now have a "buy" rating on the stock.
10/11
10:35 am
dnli
Denali Therapeutics Inc. (NASDAQ: DNLI) had its price target lowered by analysts at JPMorgan Chase & Co. from $29.00 to $28.00. They now have an "overweight" rating on the stock.
Medium
Report
Denali Therapeutics Inc. (NASDAQ: DNLI) had its price target lowered by analysts at JPMorgan Chase & Co. from $29.00 to $28.00. They now have an "overweight" rating on the stock.
10/10
09:36 am
dnli
Denali Therapeutics Inc. (NASDAQ: DNLI) had its "market perform" rating re-affirmed by analysts at Raymond James.
Low
Report
Denali Therapeutics Inc. (NASDAQ: DNLI) had its "market perform" rating re-affirmed by analysts at Raymond James.
10/7
08:10 am
dnli
Denali Therapeutics Inc. (NASDAQ: DNLI) was downgraded by analysts at Cantor Fitzgerald from an "overweight" rating to a "neutral" rating.
Medium
Report
Denali Therapeutics Inc. (NASDAQ: DNLI) was downgraded by analysts at Cantor Fitzgerald from an "overweight" rating to a "neutral" rating.
9/16
01:06 pm
dnli
Strength Seen in Denali Therapeutics (DNLI): Can Its 10.1% Jump Turn into More Strength? [Yahoo! Finance]
Low
Report
Strength Seen in Denali Therapeutics (DNLI): Can Its 10.1% Jump Turn into More Strength? [Yahoo! Finance]
9/11
04:17 am
dnli
Blood Brain Barrier Market Assessment 2024-2035, Distribution by Type of Molecule, Route of Administration, Target Disease Indication, Therapeutic Area and Key Geographical Regions [Yahoo! Finance]
Low
Report
Blood Brain Barrier Market Assessment 2024-2035, Distribution by Type of Molecule, Route of Administration, Target Disease Indication, Therapeutic Area and Key Geographical Regions [Yahoo! Finance]
9/9
12:14 pm
dnli
Denali Therapeutics Inc. (NASDAQ: DNLI) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $35.00 price target on the stock.
Low
Report
Denali Therapeutics Inc. (NASDAQ: DNLI) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $35.00 price target on the stock.
9/4
01:32 pm
dnli
Denali Plans to File for Accelerated Approval of Hunter Syndrome Drug Wed, Sep 4, 2024, 5:37 PM GMT+2 4 min read 0 In this article: Denali's Plans for Tividenofusp Alfa Denali Presents New Data on Tividenofusp Alfa Our Take DNLI's Rank and Stocks to Con
Low
Report
Denali Plans to File for Accelerated Approval of Hunter Syndrome Drug Wed, Sep 4, 2024, 5:37 PM GMT+2 4 min read 0 In this article: Denali's Plans for Tividenofusp Alfa Denali Presents New Data on Tividenofusp Alfa Our Take DNLI's Rank and Stocks to Con
9/4
08:06 am
dnli
Denali Therapeutics Inc. (NASDAQ: DNLI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Low
Report
Denali Therapeutics Inc. (NASDAQ: DNLI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
9/4
08:06 am
dnli
Denali Therapeutics Inc. (NASDAQ: DNLI) had its price target raised by analysts at Bank of America Co. from $25.00 to $29.00. They now have a "buy" rating on the stock.
Low
Report
Denali Therapeutics Inc. (NASDAQ: DNLI) had its price target raised by analysts at Bank of America Co. from $25.00 to $29.00. They now have a "buy" rating on the stock.
9/3
08:00 am
dnli
Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)
Low
Report
Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)
8/26
09:04 am
dnli
Denali Therapeutics (NASDAQ:DNLI) shareholders are up 3.4% this past week, but still in the red over the last three years [Yahoo! Finance]
Low
Report
Denali Therapeutics (NASDAQ:DNLI) shareholders are up 3.4% this past week, but still in the red over the last three years [Yahoo! Finance]